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Abstract
There is mounting evidence regarding the role of impairment in neuromodulatory networks for neurodegenerative diseases, 
such as Parkinson’s and Alzheimer’s disease. However, the role of neuromodulatory networks in multiple sclerosis (MS) 
has not been assessed. We applied resting-state functional connectivity and graph theory to investigate the changes in the 
functional connectivity within neuromodulatory networks including the serotonergic, noradrenergic, cholinergic, and dopa-
minergic systems in MS. Twenty-nine MS patients and twenty-four age- and gender-matched healthy controls performed 
clinical and cognitive assessments including the expanded disability status score, symbol digit modalities test, and Hamilton 
Depression rating scale. We demonstrated a diffuse reorganization of network topography (P < 0.01) in serotonergic, cholin-
ergic, noradrenergic, and dopaminergic networks in patients with MS. Serotonergic, noradrenergic, and cholinergic network 
functional connectivity derangement was associated with disease duration, EDSS, and depressive symptoms (P < 0.01). 
Derangements in serotonergic, noradrenergic, cholinergic, and dopaminergic network impairment were associated with 
cognitive abilities (P < 0.01). Our results indicate that functional connectivity changes within neuromodulatory networks 
might be a useful tool in predicting disability burden over time, and could serve as a surrogate endpoint to assess efficacy 
for symptomatic treatments.
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Introduction
Focal demyelination in multiple sclerosis (MS) leads to the 
disruption of the axon–myelin unit and sub-sequential neu-
ronal damage [1]. Loss of pre-synaptic neurons causes reduced 
neurotransmitter release at the synaptic cleft resulting in dis-
rupted functional connectivity among distant brain regions 
[2]. Post-mortem studies in MS reported a reduced synaptic 
density and impaired axonal transport, synaptic plasticity, glu-
tamate neurotransmission, and glutamate homoeostasis [3]. 
Demyelination, axonal loss, and synaptic pathology cause a 
dysfunctional communication among brain regions. Neurons 
throughout the brain communicate through the release of neu-
rotransmitters, subsequently modulating neuronal activity. 
Several studies have outlined neurotransmitter dysfunction in 
neurodegenerative disorders, such as Parkinson’s, Alzheimer’s, 
and Huntington’s disease, involving mainly the dopaminergic, 
serotonergic, and cholinergic networks. Network impairment 
in such neurodegenerative disorders has been selectively asso-
ciated with neurological symptoms such as cognitive, motor, 
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and non-motor symptoms [4–8]. Tools to measure impaired 
neurotransmitter networks integrity require either the applica-
tion of PET or complex MRI methodology with contrast injec-
tion. For this reason, since MS is not primarily a neurotrans-
mitter disorder, the precise involvement of neuromodulatory 
networks in MS has not been fully elucidated and existing evi-
dence is scarce. Previous studies reported that a reduced gluta-
mate and gamma-aminobutyric acid concentration throughout 
several brain areas in MS patients measured through magnetic 
resonance spectroscopy in the brain correlated with clinical 
disability [9–11].
Resting-state functional magnetic resonance imaging 
(fMRI) is able to explore connectivity in predefined networks 
as for example the default mode network, the visual network, 
and the motor network. In MS, patients could experience either 
a decrease or an increase in functional connectivity [12–16]. In 
addition, resting-state fMRI might also depict network topog-
raphy changes, through graph theoretical analyses. Graph 
theory is a mathematical representation of the brain connec-
tions, consisting of a set of nodes (corresponding to cerebral 
regions) and edges (corresponding to functional or structural 
connection) interposed between them. The topography of the 
network can be described using different measures such as 
clustering coefficient, path length, and efficiency measures to 
characterize the ‘small-world’ properties of brain networks or 
degree and betweenness centrality to identify the crucial areas 
within the network [17].
Recent evidence suggests that motor and cognitive decline 
in neurodegenerative disorders, such as Parkinson’s and Alz-
heimer’s disease, selectively depends upon neurotransmission 
integrity of dopaminergic and cholinergic networks, respec-
tively [18, 19]. We hypothesized that demyelination and axonal 
loss randomly occurring throughout the brain, in MS patients, 
might cause dysfunctional activity and, hence, impaired func-
tional connectivity (FC) in neuromodulatory networks. Fur-
thermore, clinical outcomes in MS, such as depressive symp-
toms or cognitive impairment, could depend on the integrity 
of selected neuromodulatory networks as has been observed 
in other neurological disorders, such as the selective loss of 
dopaminergic neurons in Parkinson’s disease leading to motor, 
or the loss of cholinergic neurons in Alzheimer’s disease lead-
ing to cognitive dysfunction [18, 19]. Therefore, we aimed at 
investigating FC and network topography changes within the 
serotonergic, noradrenergic, cholinergic, and dopaminergic 
networks in MS, and to explore their relationship with both 
physical and cognitive disability.
Materials and methods
Subjects
Twenty-nine patients with a definite diagnosis of relaps-
ing–remitting MS according to the 2010 revised McDon-
alds criteria [20] and twenty-four healthy controls (HCs) 
were recruited from the specialist clinics at King’s College 
Hospital NHS Foundation Trust and through advertise-
ment. All participants had no history of other neurological 
or psychiatric disorders, and were successfully screened to 
undertake MRI scanning according to the standard MRI 
scanning safety criteria (https ://www.mrisa fety.com). For 
each subject, clinical disability was assessed using the 
Expanded Disability Status Scale (EDSS). Multiple Scle-
rosis Severity Score (MSSS) was calculated as measure 
of disease severity [21]. Cognitive function was assessed 
with the symbol digit modalities test (SDMT). This test 
was chosen among other cognitive tests, because it showed 
a high sensibility and specificity in detecting cognitive 
impairment in MS [22]. The Hamilton depression rating 
scale (HRSD) was used to assess neuropsychiatric symp-
toms. The study was approved by the London-South East 
Research Ethics Committee. Written informed consent was 
obtained from all study’s subjects prior to inclusion in the 
study in accordance to the Declaration of Helsinki. Data 
will be made available via a request to the authors after a 
formal data sharing agreement.
MRI acquisition
MRI images were acquired using a 3-T Magnetom Bio-
graph mMR PET/MR hybrid scanner (Siemens, Erlangen, 
Germany). MRI sequences included three-dimensional 
magnetization-prepared rapid gradient‐echo T1 (three-
D-T1w MPRAGE, TR [repetition time]: 1700  ms, TE 
[echo time]: 2.63 ms, TI [inversion time]: 900 ms, flip 
angle: 9°, voxel size: 1.1 × 1.1 × 1.1  mm), turbo spin-
echo T2-weighed images (T2w TSE, TR: 3200 ms, TE: 
409 ms, TI: 900 ms, voxel size: 1 × 1 × 1mm); and fast 
fluid-attenuated inversion recovery (FLAIR, TR: 5000 ms, 
TE: 499 ms, TI: 1800 ms, voxel size: 1 × 1 × 1mm). In 
addition, resting-state fMRI scans were acquired using an 
echo-planar imaging sequence (TR: 3000 ms, TE: 30 ms, 
voxel size: 3 × 3 × 3mm, echo-planar imaging factor: 64, 
field of view: 192 mm, number of slices: 36; number of 
volumes: 240, flip angle: 90°).
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MR image processing
For each subject, T1 and T2 lesions were manually defined 
through Analyze medical imaging software (version 12, 
Mayo Foundation AnalyzeDirect).
T1 lesions mask was used to perform a ‘lesion filling’ 
procedure [23] on the 3D-T1w MPRAGE. We applied 
SIENAX [24] to estimate cortical gray matter volume, 
normalized for subject head size. Multi-atlas propagation 
with enhanced registration approach (MAPER) [25] method 
was applied to create the subject-specific brain segmenta-
tion. This robust, automated technique segments subjects’ 
structural T1w MRI into 95 anatomical regions with high 
accuracy and is applicable even to subjects with significant 
cortical atrophy and/or ventriculomegaly.
Structural and fMRI data were further processed analyzed 
through SPM12 software (Statistical Parametric Mapping 
version 12; https ://www.fil.ion.ucl.ac.uk/spm/softw are/
spm12 /) and the CONN toolbox version 17a [26]. Briefly, T1 
lesion-filled scans and gray matter regions of interest map 
were normalized into the Montreal Neurological Institute 
(MNI) 152 space atlas. FMRI data were realigned and co-
registered to the structural images, normalized to the MNI-
152 space atlas, and then smoothed, using 6 mm full width 
half max isotropic Gaussian kernels band-pass filtering was 
performed with a frequency window of 0.008–0.09 Hz. 
Signal contributions from micro-head movements were 
corrected using the image ‘scrubbing’ ART method imple-
mented in CONN toolbox. Outlier time points were included 
as covariates in denoising, and first-level general linear 
model along with motion parameters.
Networks’ definition
We performed a region-of-interest-based seed-to-seed con-
nectivity analysis within four selected neuromodulatory 
networks: the serotonergic, the noradrenergic, the cholin-
ergic, and the dopaminergic network. Network maps were 
created including anatomic regions of the central nervous 
system with afferent and efferent neurons using selected 
neuromodulatory molecules. To maximize the precision 
of the anatomical localization, we selected brain regions 
from subject-specific brain segmentation with the MAPER 
approach [25]. This approach allows brain segmentation in 
native space. When unavailable on the subject-specific brain 
segmentation, brain regions were selected from standard 
atlases to complete the network. For the detailed description 
of networks’ anatomy, please see Fig. 1 and Supplementary 
Appendix A-1. Briefly, the serotonergic network was created 
following Strac and colleagues, and Jacobs and Azmitia ana-
tomical description [27, 28]. The cholinergic network was 
created following Selden and colleagues anatomical descrip-
tion, including four divisions: the  Ch1-2–3 division, the  Ch4 
medial division, the  Ch4 lateral perisylvian division, and 
the  Ch4 lateral capsula division [29]. For the noradrenergic 
network, taking into account Samuels and colleagues ana-
tomical description and highly overlapping regions within 
the serotonergic network (noradrenergic network includes 
Fig. 1  Neuromodulatory networks. Cortical and subcortical projections of the neuromodulatory networks assessed in this study with the descrip-
tion of the anatomical regions selected as regions of interest
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the locus coeruleus, pedunculopontine nucleus, and ventral 
tegmental area in addition to the serotonergic network), we 
decided to merge the two networks creating a serotoner-
gic–noradrenergic network to avoid ROI overlapping [30]. 
The dopaminergic network was created following Tziortzi 
and colleagues anatomical description, including three divi-
sions: the dopaminergic executive division, the dopaminer-
gic limbic division, and the dopaminergic motor division 
excluding the ventral tegmental area already included in the 
serotonergic–noradrenergic network to avoid ROI overlap-
ping [31]. For each region of interest, we verified that the 
volume for each region was greater than the full width half 
max of the scanner resolution to avoid blurring effect. For 
each subject, we created a region of interest-to-region of 
interest serotonergic, cholinergic, noradrenergic, and dopa-
minergic functional connectivity matrix in MNI space.
Graph theory measures
For each network matrices, we performed a network topo-
graphic analysis through CONN functional connectivity 
toolbox [26]. We used a set of functional connectivity indi-
ces, namely the global efficiency, the local efficiency, the 
betweenness centrality, the average path length, the clus-
tering coefficient, and the degree [17]. Global efficiency is 
a measure of network integration describing the informa-
tion flow over the whole network. Local efficiency is the 
distance between the nodes and is a measure of network 
integration. Betweenness centrality is a measure of network 
centrality; it corresponds to the fraction of all the shortest 
paths in a network over a given node. Nodes with higher 
betweenness centrality participate in a large number of 
short paths. Average path length corresponds to the shortest 
distance between pairs of nodes, and is a measure of net-
work efficiency of information transfer within the network. 
An increased average path length reflects the inability of 
the network to transfer information in parallel. Clustering 
coefficient is a measure of network organization reflecting 
the number of connections between the neighbor’s nodes. 
Degree is a measure of centrality and reflects the number 
of connections for each node to all other nodes in the net-
work. A higher degree means a greater influence of the cor-
responding region in the network. To extract the best indices 
of network organization, network edges were adjusted with a 
threshold for a cost higher than 0.15 on a two-sided test for 
the adjacency matrix [32].
Statistics
Statistical analyses were performed through CONN func-
tional connectivity toolbox using a seed-to-seed approach 
in SPM. Between-group analysis was performed using 
two-tailed t tests to compare the resting-state functional 
connectivity and graph theory measures change between 
MS patients and HCs for each network. Linear regression 
analysis was also performed to investigate the association 
between clinical disability and both the resting-state func-
tional connectivity and graph theory measures for each 
neurotransmitter network for MS patients. Linear regres-
sion was performed only for those networks that showed a 
difference at the between-group analysis. Age and gender 
were included in the analysis as covariates for the between-
group comparison, while age, gender, cortical gray matter 
volume and T2 lesions volume were used as covariate for 
the linear regression analyses with the EDSS, SDMT, and 
HRSD as dependent variables. Only age and gender were 
included as covariates for the linear regression analyses with 
disease duration and disease severity as dependent variable, 
considering the close interaction between these two latter 
variables and both lesion volume and cortical atrophy. Given 
the exploratory nature of the study, a threshold of P < 0.01 
uncorrected was applied for between-groups and linear 
regression data analyses. Notwithstanding the exploratory 
nature of the study, we also applied the Benjamini–Hoch-
berg procedure to control for the false discovery rate when 
evaluating correlation matrices in the FC analysis, setting 
the false discovery rate to 10% [33].
Results
Clinical assessments
MS patients performed worse than HCs in the SDMT 
(P < 0.001) and scored higher in HRSD (P < 0.001). Clini-
cal, demographic, and imaging characteristics of the HCs 
and MS patients are summarized in Table 1.
Functional connectivity in  serotonergic–
noradrenergic network
MS patients showed decreased resting-state functional con-
nectivity between different cerebellum regions (P = 0.006) 
and between the cerebellum and both the right amygdala 
and right thalamus (P < 0.01) compared with HCs. Patients 
also showed increased resting-state functional connectivity 
between the dorsal raphe and both the left and right supe-
rior frontal gyrus (P < 0.001), between the dorsal raphe and 
the left middle frontal gyrus, (P = 0.002), and between the 
left globus pallidus and the right hippocampus (P = 0.001) 
compared with HCs (Table 2 and Fig. 2).
Graph theory analysis revealed that MS patients 
showed increased betweenness centrality in the cerebellum 
(t-value = 2.84; P = 0.007) and a decreased betweenness cen-
trality in the brainstem (t value = − 3.03; P = 0.004) for the 
serotonergic–noradrenergic network (Table 3 and Fig. 3).
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Table 1  Demographic, clinical 
and radiological features of 
Multiple Sclerosis patients and 
healthy controls
N number, SD standard deviation
Characteristic MS patients Healthy Controls P value
Subjects 29 24 –
Female sex, N (%) 17 (59) 15 (63) 0.8
Age, mean ± SD (years) 42.7 ± 8.2 38.2 ± 8.4 0.06
Disease duration, mean ± SD (years) 10.8 ± 1.5 – –
EDSS, mean ± SD 3.2 ± 1.3 – –
MSSS, mean ± SD 4.2 ± 2 – –
Log.T2 lesional load  (mm3), median (range) 3.47 (0.48–29.50) – –
Timed 25-foot walk (s), mean ± SD 20.7 ± 10.5 16.6 ± 6.01 0.20
Raw SDMT score, mean ± SD 40.6 ± 9.8 54.5 ± 9.66  < 0.001
HRSD, mean ± SD 6.39 ± 4.21 0.56 ± 0.96  < 0.001
Disease modifying treatment
None, N (%) 7 (24) –
Interferon β1-a, N (%) 2 (7) –
Dimethyl fumarate, N (%) 7 (24) –
Teriflunomide, N (%) 1 (3.5) –
Fingolimod, N (%) 7 (24) –
Natalizumab, N (%) 1 (3.5) –
Alemtuzumab, N (%) 3 (10.5) –
Daclizumab, N (%) 1 (3.5) –
Table 2  Brain areas showing significant differences of resting state functional MRI between healthy controls and multiple sclerosis patients 
within each neurotransmitter network
Comparisons were performed using the contrast multiple sclerosis patients > healthy controls (two-tailed t test adjusted for age and gender, 
P < 0.01 uncorrected). T values are reported. Negative T values refer to a reduced connectivity between the source and target regions in multiple 
sclerosis patients compared to healthy controls
* Significant after FDR correction
Neurotransmitter network Source Target T value P value FDR-
adjusted P 
value
Serotonergic–noradrenergic Dorsal raphe Superior frontal gyrus right 4.04  < 0.001  < 0.001*
Superior frontal gyrus left 3.62  < 0.001  < 0.001*
Middle frontal gyrus left 3.34 0.002 0.001
Cerebellum-Crus I right Amygdala right − 2.76 0.008 0.002
Thalamus right − 2.71 0.009 0.002
Cerebellum-Vermis Crus II Cerebellum-Left VIIb − 2.88 0.006 0.002
Globus pallidus left Hippocampus right 3.36 0.001 0.001
Cholinergic
Ch4 lateral capsula division Ch4 nucleus Superior frontal gyrus left − 3.51 0.001  < 0.001*
Middle frontal gyrus right − 3.47 0.001 0.001*
Superior frontal gyrus right − 3.01 0.004 0.002
Middle frontal gyrus left − 2.87 0.006 0.003
Posterior cingulate gyrus left Cuneus left − 2.91 0.005 0.003
Middle temporal gyrus left Precentral gyrus left 3.47 0.001 0.001*
Middle frontal gyrus left 3.3 0.002 0.002
Postcentral gyrus right 3.22 0.002 0.002
Precentral gyrus right 3 0.004 0.003
Postcentral gyrus left 2.89 0.006 0.003
Fusiform gyrus right Inferior frontal gyrus left 2.73 0.009 0.004
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Functional connectivity in cholinergic network
Ch1‑2‑3 division
Regarding  Ch1-2-3 division of the cholinergic network, MS 
patients showed no differences for both functional con-
nectivity and graph theory evaluation compared to HCs.
Ch4 medial division
Functional connectivity evaluation for the  Ch4 medial 
division of the cholinergic network showed no difference 
between HCs and MS patients. Graph theory analysis 
revealed that MS patients have a higher local efficiency (t 
value = 0.36; P = 0.006) and a higher clustering coefficient 
Fig. 2  Resting-state functional connectivity changes in multiple scle-
rosis. Abnormalities of resting-state functional connectivity in mul-
tiple sclerosis (MS) patients compared to healthy controls (HCs) in 
the different neuromodulatory networks. Blue connections represent 
a decreased functional connectivity between the two regions of inter-
est in MS patients compared to HCs. Red connections represent an 
increase functional connectivity between the two regions of interest 
in MS patients compared to HCs
Table 3  Brain areas showing 
significant differences for 
graph theory measures between 
healthy controls and multiple 
sclerosis patients within each 
neurotransmitter network
Comparisons were performed using the contrast multiple sclerosis patients > healthy controls (two-tailed t 
test adjusted for age and gender, P < 0.01 uncorrected). T values are reported. Negative t values refer to a 
reduced value for the graph analysis measure in the selected region of interest in multiple sclerosis patients 
compared to healthy controls
Neurotransmitter network Graph theory measure Region of interest T value P value
Serotonergic–noradrenergic Betweenness centrality Brainstem − 3.03 0.004
Cerebellum-right VIIIa 2.84 0.007
Cholinergic
Ch4 medial division Local efficiency Anterior cingulate gyrus left 0.36 0.006
Clustering coefficient Anterior cingulate gyrus left 0.34 0.007
Cholinergic
Ch4 lateral perysilvian division Betweenness Centrality Posterior insula right − 3.02 0.004
Average path length Middle insula left − 2.94 0.005
Cholinergic
Ch4 lateral capsula division Global efficiency Superior parietal gyrus right − 2.85 0.006
Middle frontal gyrus left 2.73 0.009
Average path length Middle frontal gyrus left − 3.4 0.001
Postcentral gyrus right − 2.79 0.007
Postcentral gyrus left − 2.78 0.008
Inferior frontal gyrus left − 2.76 0.008
Degree Superior parietal gyrus right − 2.85 0.006
Dopaminergic
Motor division Degree Middle frontal gyrus right − 2.86 0.006
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(t-value = 0.34; P = 0.007) compared with HCs for the  Ch4 
medial division of the cholinergic network (Table 3 and 
Fig. 3).
Ch4 lateral perisylvian division
MS patients have a similar functional connectivity for the 
 Ch4 lateral perisylvian division of the cholinergic network 
compared with HCs, whereas they showed a decreased 
betweenness centrality in the right insula (t-value = -3.02; 
P = 0.004) and a decreased average path length in the left 
insula (t value = -2.94; P = 0.005) compared with HCs when 
evaluating the network topography through graph theory 
(Table 3 and Fig. 3).
Ch4 lateral capsula division
Resting-state fMRI evaluation revealed that MS patients, 
compared with HCs, have reduced functional connectivity 
between the  Ch4 nucleus and both the middle and superior 
frontal gyrus (all P < 0.006), and between the left posterior 
cingulate cortex and the left cuneus (t-value = − 2.91; 
P = 0.005). MS patients also showed an increased con-
nectivity between the left middle temporal gyrus and the 
right middle temporal gyrus (t-value = − 3.3; P = 0.002), 
between the left middle temporal gyrus and both the left 
and right pre- and post-central gyrus (all P < 0.006), and 
between the right fusiform gyrus and the left inferior fron-
tal gyrus (t-value = 2.73; P = 0.009) (Table 2 and Fig. 2).
Graph theory assessment showed that MS patients 
have a reduced global efficiency in the right superior 
frontal gyrus (t-value = −  2.85; P = 0.006), a reduced 
average path length in the left middle frontal gyrus 
(t-value = − 3.4; P = 0.001), in the right and left post-
central gyrus (t-value = − 2.79; P = 0.008), and in the 
left inferior frontal gyrus (t-value = − 2.76; P = 0.008), 
and a reduced degree in the right superior frontal gyrus 
(t-value = − 2.85, P = 0.006) compared with HCs for the 
 Ch4 lateral capsula division of the cholinergic network. 
MS patients also showed an increased global efficiency 
in the left middle frontal gyrus (t-value = 2.73; P = 0.009) 
(Table 3 and Fig. 3).
Fig. 3  Graph theory measures between healthy controls and multiple 
sclerosis patients within each neuromodulatory networks. Brain areas 
showing significant differences for graph theory measures between 
healthy controls (HCs) (in black) and multiple sclerosis (MS) patients 
(in white) within the neuromodulatory networks. Comparisons were 
performed using the contrast MS patients > HCs (two-tailed t test 
adjusted for age and gender, P < 0.01 uncorrected). Data represent 
mean ± standard deviations
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Functional connectivity in dopaminergic network
Executive division
MS patients showed no differences for both functional con-
nectivity and graph theory evaluation for the executive divi-
sion of the dopaminergic network.
Limbic division
MS patients showed no differences for both functional con-
nectivity and graph theory evaluation for the executive divi-
sion of the dopaminergic network.
Motor division
MS patients showed no differences in resting-state functional 
connectivity when compared with HCs for the motor divi-
sion of the dopaminergic network. Conversely, for the same 
network, graph theory analysis revealed that MS patients 
showed a decreased degree in the right middle frontal gyrus 
compared with HCs (t-value = − 2.86; P = 0.006) (Table 3 
and Fig. 3).
Clinical correlation analysis
Disease duration correlated with changes in the FC within 
the serotonergic–noradrenergic network(between cerebel-
lum and right superior frontal gyrus, t-value = − 3.54,amyg-
dala right and dorsal raphe, t-value = − 3.49, cerebellum 
andleft inferior frontal gyrus, t-value = 3.54,right putamen 
and left globus pallidus, t-value = -2.92,cerebellum and 
right globus pallidus, t-value = − 3.29,ventral tegmental 
area and cerebellum, t-value = 3.54; all P < 0.01; Supple-
mentary Table B-1), and the  Ch4 lateral capsula division 
of the cholinergic network (between left inferior frontal 
gyrus and right amygdala, t-value = 3.67,  right parahip-
pocampal gyrus and left occipital lobe, t-value = − 2.87; 
all P < 0.01; Supplementary Table B-1). Similarly, disease 
duration also correlated with changes in the graph theory 
measures in the serotonergic–noradrenergic network,and the 
 Ch4 lateral capsula and  Ch4 lateralperisylvian divisions of 
the cholinergic network (all P < 0.01; Supplementary Table 
B-2). EDSS was associated with changes in FC within the 
serotonergic–noradrenergic network (between cerebellum 
and left middle frontal gyrus, t-value = − 3.75, right hip-
pocampus and left putamen, t-value = − 3.04, right puta-
men and right hippocampus, t-value = - 3.52; all P < 0.01; 
Supplementary Table B-1), the  Ch4 lateral capsula division 
of the cholinergic network (between left superior temporal 
gyrus and left cuneus, t-value = 3.18, and  Ch4 nucleus and 
left angular gyrus, t-value = 3.25, right amygdala and right 
lingual gyrus, t-value = − 3.80; all P < 0.01; Supplementary 
Table B-1). EDSS was also associated with changes in the 
graph theory measures for the serotonergic–noradrenergic 
network, for the  Ch4 lateral capsula division and  Ch4 lateral 
perisylvian division of the cholinergic network, and for the 
motor division of the dopaminergic network (all P < 0.01; 
Supplementary Table B-2).
Disease severity, assessed with MSSS, correlated with 
changes in the FC in the serotonergic–noradrenergic network 
(between dorsal raphe and right amygdala, t-value = 3.60, 
left thalamus and left putamen, t-value = − 3.12, within the 
cerebellum, t-value = − 2.93; all P < 0.01; Supplementary 
Table B-1). Disease severity also correlated with changes in 
the graph theory measures for the serotonergic–noradrener-
gic network, for the  Ch4 lateral perisylvian division of the 
cholinergic network, and for the motor division of the dopa-
minergic network (all P < 0.01) (Supplementary Table B-2).
Cognitive function, assessed with the SDMT, corre-
lated with changes in the resting-state FC in the serotoner-
gic–noradrenergic network (between right caudate nucleus 
and right inferior frontal gyrus, t-value = 4.25, cerebellum 
and left putamen, t-value = − 6.44, cerebellum and left hip-
pocampus, t-value = − 4.04, right hippocampus and right 
caudate nucleus, t-value = 5.37, left hypothalamus and 
right putamen, t-value = 4.12, right inferior frontal gyrus 
and left superior frontal gyrus, t-value = 4.20, left puta-
men and left caudate nucleus, t-value = 4.04; right thalamus 
and cerebellum, t-value = − 4.19; locus coeruleus and right 
hippocampus, t-value = − 4.16; ventral tegmental area and 
left superior frontal gyrus, t-value = 6.71; all P < 0.01, Sup-
plementary Table B-1), the  Ch4 lateral capsular division of 
the cholinergic network (between right angular gyrus and 
left fusiform gyrus, t-value = − 4.52, right fusiform gyrus 
and right precentral gyrus, t-value = − 4.24, right posterior 
cingulate cortex and left occipital lobe, t-value = 6.60; all 
P < 0.01; Supplementary Table B-1), and the limbic divi-
sion of the dopaminergic network (between left anterior cin-
gulate cortex and left medial orbital gyrus, t-value = 5.77, 
left medial orbital gyrus and left anterior cingulate cortex, 
t-value = 3.90; all P < 0.01; Supplementary Table B-1). 
SDMT also correlated with changes in the graph theory 
measures for the serotonergic–noradrenergic network and 
for the  Ch4 lateral perisylvian division of the cholinergic 
network (all P < 0.01; Supplementary Table B-2).
Depressive symptoms, assessed through the HRSD, 
were associated with changes in the resting-state FC for 
the serotonergic–noradrenergic network (between cerebel-
lum and left nucleus accumbens, t-value = − 4.75, cerebel-
lum and right hypothalamus, t-value = − 4.17, brainstem 
and left hypothalamus, t-value = − 5.53, cerebellum and 
right amygdala, t-value = 10.05, cerebellum and left hip-
pocampus, t-value = − 4.14, cerebellum and right thala-
mus, t-value = 5.63; cerebellum and locus coeruleus, 
t-value = − 4.17; cerebellum and ventral tegmental area, 
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t-value = 4.47; all P < 0.01; Supplementary Table B-1), and 
the  Ch4 lateral capsula division of the cholinergic network 
(between  Ch4 nucleus and right angular gyrus, t-value = 4.05, 
right amygdala and Postcentral gyrus left, t-value = 4.56, 
left amygdala and left supramarginal gyrus, t-value = 4.07; 
all P < 0.01; Supplementary Table B-1). HRSD correlated 
with changes in the graph theory measures for the seroton-
ergic–noradrenergic network (all P < 0.01; Supplementary 
Table B-2).
Discussion
Using a resting-state fMRI, we demonstrated FC changes 
and network topography derangements in serotonergic, 
noradrenergic, cholinergic, and dopaminergic systems. We 
highlighted that these changes has direct clinical implica-
tions resulting in both physical and cognitive disability in 
MS patients.
In MS, changes in network connectivity and topography 
within serotonergic, noradrenergic, cholinergic, and dopa-
minergic networks were not completely unexpected. First, 
the random occurrence of demyelinating lesions throughout 
the brain may cause white matter tract disconnection and 
brain reorganization, resulting in impaired FC. Considering 
the many long-range and diffuse projections to both corti-
cal and subcortical regions from the relatively small cell 
populations that produce modulatory neurotransmitters (e.g., 
dorsal Raphe,  Ch4 nucleus, and locus coeruleus), it is rea-
sonable to expect that these neurochemical networks would 
be highly susceptible to white matter pathologies. Further-
more, given the wide range of physiological processes that 
these modulatory transmitter populations are implicated in 
it, quantification of functional changes in their associated 
networks could well provide a guide to the development and 
progression of clinical symptoms in MS. However, patholog-
ical changes lead to structural and functional reorganization 
of the brain to compensate for the loss of functions. Brain 
reorganization in MS is a dynamic process, likely character-
ized by increased FC as a compensatory mechanism during 
early stages and reduced ability to compensate for progres-
sive brain damage at later stages, subsequently resulting in 
decreased FC [14]. Therefore, we cannot completely rule out 
the role of spatial reorganization of network anatomy in MS 
patients following brain damages. However, to partly over-
come this issue, we used subject-specific regions of interest 
map, which allow us to take into account the subject ana-
tomical variability and brain changes that might occur dur-
ing the disease course, for example brain atrophy. Although 
ROI selection was performed to avoid brain regions over-
lapping, between the neuromodulatory networks due to the 
fact that in one single cortical area, we might find neuronal 
subpopulation belonging to different neuromodulatory 
networks, we cannot completely disentangle the role of each 
sub-population to the connectivity within the explored net-
work. Notwithstanding this limitation, our exploratory study 
might drive new studies aimed at evaluating neuromodu-
latory network changes in MS taking advantage of newly 
developed PET tracers for neurotransmitters which are better 
equipped to dissociate neuromodulatory components in, for 
example, the dorsal raphe or cholinergic nuclei. Similarly, 
the reported alterations in FC might not necessarily imply a 
selective derangement in neuromodulatory networks, since 
they could reflect changes in non-neuromodulatory networks 
partly overlapping in terms of brain regions. Nonetheless 
these limitations, our results are consistent with the previous 
results. Hesse and colleagues reported reduced brain seroto-
nin transporter levels in the cingulate cortex, the thalamus, 
and the insula, and a higher transporter availability in the 
orbitofrontal cortex in MS patients compared to HCs using 
PET molecular imaging with the radiotracer  [11C]DASB 
[34]. In our study, we found reduced functional connectiv-
ity within the cerebellum, and between the cerebellum and 
both the amygdala and the thalamus, whereas there was an 
increased connectivity between the dorsal raphe and the 
frontal regions. In addition, we also outlined a decreased 
betweenness centrality for the brainstem in MS compared to 
HCs, suggesting that ascending projections from this struc-
ture are damaged and have a reduced activity in controlling 
the cortical regions of the network.
Differently for the serotonergic network, very little is 
known about noradrenalin deficits in MS. Noradrenalin 
concentration in the brain of MS patients was found to be 
either increased [35] or decreased [36]. The primary source 
of noradrenalin in the brain is the locus coeruleus [37]. Both 
inflammation and neurodegeneration have been described 
within the locus coeruleus of MS patients and the extent of 
neuronal damage shown to correlate with cognitive disabil-
ity [38, 39]. Therefore, the reduced centrality of the brain-
stem in the noradrenalin network, reported in here, might be 
related to an overall reduced activity of the locus coeruleus 
with reduced function of the long-range projections heading 
to frontal regions and adaptive short-path intra-cerebellum 
adaptive connections, which increase the dysfunctional cen-
trality of the cerebellum.
In our study, we also reported a functional disconnec-
tion between cortical and subcortical regions modulated by 
cholinergic neurons, with direct implications for cognition. 
Kimura and colleagues already reported tissue damage in 
the white matter bundles of the cholinergic network using 
a semi-quantitative measure and a correlation with cogni-
tive impairment [40]. Finally, we also reported altered FC 
in the dopaminergic network in MS patients compared to 
HCs, showing a decreased connectivity between the ven-
tral tegmental area and the orbital cortex and a decreased 
degree in the middle frontal gyrus. Up to now, no studies 
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have specifically assessed dopaminergic network in MS. 
However, indirect report outlined the occurrence of white 
matter lesions over the bundles connecting the substantia 
nigra, the ventral tegmental areas, the striatum, the limbic 
areas, and the prefrontal cortex with changes in the local 
metabolic activity in the prefrontal cortex and in the stria-
tum [41–43]. These damages may underpin FC changes and 
network reorganization, and are associated with cognitive 
impairment and fatigue [44–46].
Regarding clinical outcome measures, disease duration, 
disease severity, and physical disability were also associ-
ated at different extent with FC and network topography 
changes within serotonergic, cholinergic, dopaminergic, and 
noradrenergic network. We also reported a link between net-
works derangement and SDMT scores, suggesting a role for 
cognitive impairment. However, the SDMT is a single test 
assessing attention and information processing speed, thus 
exploring only a single cognitive domain. A more extensive 
cognitive battery, assessing different cognitive domains, 
such as the Brief Repeatable Battery of Neuropsychological 
Tests [47], could better elucidate the relationship between 
cognitive impairment and networks derangements. The asso-
ciation between network impairment and disease burden was 
evident especially for those networks with a wider distribu-
tion throughout the brain. This might be possibly due to 
a lower probability of demyelinating lesions over the con-
necting fiber bundles and subsequent disruption of neuron 
communication. Moreover, it is worth mentioning that both 
disease modifying and concomitant treatments, especially 
those aiming at providing relief from depressive symptoms, 
might impact on FC in neuromodulatory networks. The 
small sample in the present study prevents us from being 
able to draw conclusions on this topic. Further studies with 
larger samples, and targeted study design, are warranted to 
better evaluate the impact of disease modifying and concom-
itant therapies on FC changes in neuromodulatory networks. 
Therefore, the overall neurotransmitter network impairment 
might be used as a marker of brain damage and could be 
useful to stratify patients according to the severity of the 
disease.
In addition, we reported an association between depres-
sive symptoms and both serotonergic and noradrenergic 
network topography reorganization. Our findings are in 
line with the reduction in the monoamine network activ-
ity, namely noradrenalin and serotonin, in major depres-
sive disorder [48] and in MS [34]. In addition, we found 
that depression in MS was associated with an increased 
connectivity throughout the cholinergic network. This 
is in line with the previous findings describing an asso-
ciation between depressive symptoms and over-activity 
of the cholinergic system throughout the brain [49, 50]. 
Taken together, these findings suggest that depressive 
symptoms in MS are highly dependent upon neurotrans-
mission integrity and an integrated therapeutic approach 
using drugs targeting different neurotransmitters might be 
useful. Moreover, depressive symptoms in MS include a 
broad spectrum of symptoms such as decreased concentra-
tion, fatigue, and sexual disinterest. Understanding better 
the neuronal basis of each of these symptoms might help 
clinicians towards more targeted symptomatic treatment 
choices to obtain a higher treatment efficacy.
Conclusions
Through utilization of resting-state fMRI, and adopting 
an innovative method for reconstructing neuromodulatory 
networks maps in a subject-specific fashion, we revealed 
a diffuse FC impairment and topography derangements 
within the serotonergic, noradrenergic, cholinergic, and 
dopaminergic networks in MS with direct impact on clini-
cal disability. This is the first study investigating neuro-
transmitter pathology in MS. Considering that resting-state 
fMRI might not disentangle FC changes specifically due 
to neuro-modulatory damages from those related to non-
neuromodulatory connections, further studies assessing 
the impairment for each individual network using selec-
tive PET tracers are highly warranted to better understand 
the role of each network in disease pathophysiology and 
drive towards clinical applications of these findings. Neu-
rotransmitter impairment might be a predictor of disability 
burden over time and might be used ideally to assess treat-
ment efficacy. Moreover, confirmatory studies might also 
lead to the development of new symptomatic treatment 
based on neurotransmitter modulation.
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